Application of marker of proliferative activity Ki-67 for analysis of efficacy in complex treatment of patients, suffering locally-spread mammary gland cancer

Abstract

Objective. Application of the proliferative activity marker Ki-67 for analysis of the results of neoadjuvant polychemotherapy, using regional or systemic ways of delivery of pharmacological preparations, for the patients, suffering locally spread mammary gland cancer (LS MGC).
 Materials and methods. Retrospective analysis of the data, concerning 90 women-patients, suffering LS MGC, who obtained complex treatment, based on regional and systemic ways of the preparations administration.
 Results. Dynamics of proliferative activity of a LS MGC as a result of neoadjuvant polychemotherapy, analyzed by the Ki-67 level determination, have demonstrated a statistically significant advantage of regional ways of the preparation injection, comparing with systemic ways of administration. Correlation of tumoral metastatic potential with level of Ki-67 was revealed, using detailed investigation.
 Conclusion. It is possible to estimate tumoral proliferative activity and the neoadjuvant polychemotherapy efficacy, using Ki-67 analysis, and in such a way to select the optimal tactics of complex treatment.